If you or a loved one has taken Reglan (metoclopramide) and noticed involuntary muscle movements, you may be concerned about tardive dyskinesia. The FDA has issued a black box warning on this medication, reflecting serious risks with long-term use. This page explains what that warning means, who is at risk, and how to recognize early symptoms.
Reglan (metoclopramide) is a prescription medication approved for short-term treatment of symptomatic gastroesophageal reflux in adults who have not responded to conventional therapy, and for relief of symptoms in adults with acute and recurrent diabetic gastroparesis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The drug carries a boxed warning stating that metoclopramide, including Reglan, can cause tardive dyskinesia (TD), a potentially irreversible serious movement disorder (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The risk of developing TD increases with duration of treatment and total cumulative dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Reglan is contraindicated in patients with a history of TD, and the label instructs prescribers to use the drug for the shortest duration necessary and to periodically reassess the need for continued treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). For patients with symptomatic, documented gastroesophageal reflux, the maximum duration of Reglan treatment is 12 weeks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). In patients with diabetic gastroparesis, the label advises avoiding total treatment duration longer than 12 weeks; if longer-term use is unavoidable, routine monitoring for signs and symptoms of TD is recommended (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Tardive dyskinesia is characterized by potentially irreversible and disfiguring involuntary movements of the face or tongue, and sometimes of the trunk and/or extremities (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The label notes that metoclopramide may suppress or partially suppress the signs of TD, potentially delaying diagnosis because it can mask the underlying disease process (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).
The mechanistic pathway linking Reglan to TD involves the drug's dopamine receptor-blocking properties in the basal ganglia, which can lead to supersensitivity of dopamine receptors and subsequent abnormal involuntary movements. The label also warns against concomitant use of other drugs known to cause TD, extrapyramidal symptoms, or neuroleptic malignant syndrome, and advises avoiding use in patients with Parkinson's disease (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). If symptoms of TD occur, immediate discontinuation of Reglan and medical attention are recommended (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). From a risk perspective, the adequacy of warnings regarding Reglan and TD is a central concern. The boxed warning is prominent, but the label also includes limitations of use: Reglan has not been shown to be safe and effective for gastroesophageal reflux for longer than 12 weeks, and the tablets are not recommended for pediatric patients due to the risk of TD and other extrapyramidal symptoms, as well as methemoglobinemia in neonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Despite these warnings, cases of TD have occurred in patients who used Reglan for extended periods, sometimes exceeding the recommended 12-week limit. The timeline between exposure and documented harm can vary; TD may develop during treatment, after discontinuation, or even months later. The label states that the risk increases with duration and cumulative dose, but individual susceptibility also plays a role. For affected patients in Pennsylvania, attorney-related considerations include the statute of limitations for filing a claim. In Pennsylvania, the statute of limitations for personal injury claims, including those related to prescription drug injuries, is generally two years from the date the injury was discovered or reasonably should have been discovered. For TD, the discovery date may be when a patient first notices abnormal movements or receives a formal diagnosis. Given that TD can be irreversible, early legal consultation is advisable to preserve the right to seek compensation. Patients should gather medical records documenting Reglan use, the duration of treatment, and the onset of TD symptoms. The label's explicit warnings about TD and the recommended 12-week maximum duration may be relevant in demonstrating that the manufacturer provided adequate warnings, but the adequacy of those warnings in practice—such as whether prescribers and patients were sufficiently informed—can be a point of contention. In summary, Reglan carries a known risk of causing tardive dyskinesia, a potentially irreversible movement disorder. The drug's labeling includes a boxed warning, contraindications, and duration limits, but cases of TD continue to occur, often after prolonged use. Patients in Pennsylvania who develop TD after using Reglan should be aware of the two-year statute of limitations and seek legal advice promptly to evaluate their options.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
In Pennsylvania, the statute of limitations for personal injury claims, including those related to prescription drug injuries like tardive dyskinesia from Reglan, is generally two years from the date the injury was discovered or reasonably should have been discovered. For TD, this is typically when a patient first notices abnormal movements or receives a formal diagnosis.
While the risk of developing tardive dyskinesia increases with duration of treatment and total cumulative dosage, cases have occurred even with shorter use. The label recommends using Reglan for the shortest duration necessary, and for gastroesophageal reflux, the maximum is 12 weeks. However, individual susceptibility varies, and TD can develop during treatment, after discontinuation, or months later.
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Request archival records or inquire about member-exclusive transition and benefit programs.
Individuals with documented archive exposure and a related diagnosis may request an independent, no-cost eligibility review.